Skip to main content

Table 1 Baseline characteristics of ≤ 2-year old malarious children at enrolment according to year and site of study

From: Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under

Study site (year of study)a No. of children Gender Age (year) Weight (kg) Duration (days) Temperature (°C) Haematocrit (%) Degree of anaemia Parasitaemia (μL−1)
M/F Mean ± sd (Range) No. <1 year Mean ± sd (Range) Mean ± sd (Range) Mean ± sd (Range) No. >37.4 °C No. ≥40 °C Mean ± sd (Range) No. < 30 % Mild Moderate Severe Geometric mean (Range) No. >100,000 μL−1
Ibadan (2005–2010) 47 26/21 1.7 ± 0.4 (0.7–2) 4 9.7 ± 2.5 (6–17) 2.9 ± 1.5 (1–7) 38.5 ± 1.1 (36.1–40.8) 39 2 28.3 ± 4.5 (20–38) 26 23 3 - 30,924 (1,614–304,500) 7
Damboa (2009–2010) 24 16/8 1.5 ± 0.5 (0.5–2) 7 9.9 ± 3.9 (5–20) - 37.9 ± 0.6 (37.5–39.3) 24 - 27.9 ± 5.9 (14–36) 12 9 2 1 5,988 (1,000–123,774) 1
Agbani (2009–2010) 57 24/33 1.3 ± 0.5 (0.5–2) 20 9.9 ± 1.7 (5–17) - 37.6 ± 1.1 (35.6–40.3) 30 1 27.3 ± 4.3 (18–40) 38 33 5 - 10,343 (1,018–155,520) 3
Makarfi (2009–2010) 41 24/17 1.4 ± 0.4 (0.5–2) 15 8.4 ± 1.6 (5–12) - 37.9 ± 1 (36–39.4) 29 - 29.4 ± 5.1 (16–37) 15 13 2 - 10,208 (1,301–112,421) 2
Ijede (2009–2010) 28 18/10 1.4 ± 0.4 (0.6–2) 6 9.2 ± 1.6 (5–12) - 38.1 ± 1.4 (36–40.3) 18 4 28.9 ± 4.8 (19–38) 16 14 2 - 10,788 (1,071–78,769) -
Barkin Ladi (2009–2010) 39 20/19 1.6 ± 0.5 (0.6–2) 8 10.6 ± 2.3 (7–15) 3.1 ± 1 (1–7) 37.9 ± 1 (36.1–40) 30 1 30.7 ± 4.2 (22–40) 13 13 - - 17,336 (2,132–104,154) 1
Ibadan (2011–2015) 14 11/3 1.4 ± 0.6 (0.5–2) 5 9.2 ± 2.8 (5–14) 3 ± 0.7 (2–4) 38.1 ± 1.3 (36.3–40) 9 1 29 ± 4.1 (22–37) 7 7 - - 23,326 (2,924–114,504) -
ALL (2005–2015) 250 139/111 1.5 ± 0.5 (0.5–2) 65 9.6 ± 2.3 (5–20) 3 ± 1.2 (1–7) 38 ± 1.1 (35.6–40.8) 179 9 28.7 ± 4.8 (14–40) 127 112 14 1 13,714 (1000–304,500) 16
P value - 0.14 0.03 0.03 0.001 0.83 0.01 0.02 0.29 0.03 0.02 0.85 0.99 - <0.0001 0.11
  1. sd standard deviation
  2. aartesunate-amodiaquine and artemether-lumefantrine were evaluated at all sites